Factors determining sensitivity or resistance of tumor cell lines towards artesunate

Chemico-Biological Interactions

Volumn 185, Issue 1, 2010, Pages 42-52

  Sertel, Serkan ^a,b   Eichhorn, Tolga ^b   Sieber, Sebastian ^b   Sauer, Alexandra ^a   Weiss, Johanna ^a   Plinkert, Peter K ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anti cancer therapy; Artemisinin; Artesunate (ART); Molecular pharmacology; Multidrug resistance (MDR); Natural products; Pharmacogenomics; Traditional Chinese medicine (TCM)

Indexed keywords

ARTESUNATE; BETA1 INTEGRIN; BINDING PROTEIN; BONE MARROW STROMAL CELL ANTIGEN 1; CATALASE; CHAPERONE ABC1 ACTIVITY OF BC1 COMPLEX HOMOLOG PROTEIN; CHAPERONIN CONTAINING TCP1 SUBUNIT 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOPAMINE BETA MONOOXYGENASE; ELONGATION FACTOR TU; FILAMIN A; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; NCK ASSOCIATED PROTEIN 1; PHOSPHOTRANSFERASE; PROTEIN E6; PROTEIN P21; PROTEIN P53; PROTEIN S6; RIBOSOMAL PROTEIN L41; RIBOSOMAL PROTEIN L6; RIBOSOMAL PROTEIN L7; RIBOSOMAL PROTEIN S12; RIBOSOMAL PROTEIN S15A; RIBOSOME PROTEIN; SOLUTE CARRIER FAMILY 25 MEMBER 19; SPLICING FACTOR ARGININE SERINE RICH 2 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC FINGER AND BTB DOMAIN CONTAINING 4 PROTEIN;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IC 50; NEOPLASM; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; TUMOR CELL LINE;

ANTIMALARIALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARTEMISININS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

ARTESUNATE; HUMAN PAPILLOMAVIRUS;

EID: 77950958513     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.02.002     Document Type: Article

References (73)

1. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 2007, 5(3):203-220.
2. Efferth T., Gebhart E., Ross D.D., Sauerbrey A. Identification of gene expression profiles predicting tumor cell response to l-alanosine. Biochem. Pharmacol. 2003, 66(4):613-621.
3. Efferth T., Miyachi H., Drexler H.G., Gebhart E. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. Blood Cells Mol. Dis. 2002, 28(1):47-56.
4. Shankar S., Srivastava R.K. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv. Exp. Med. Biol. 2008, 615:261-298.
5. Muller S., Murillo R., Castro V., Brecht V., Merfort I. Sesquiterpene lactones from Montanoa hibiscifolia that inhibit the transcription factor NF-kappa B. J. Nat. Prod. 2004, 67(4):622-630.
6. Efferth T., Li P.C., Konkimalla V.S., Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 2007, 13(8):353-361.
7. Efferth T., Rauh R., Kahl S., Tomicic M., Bochzelt H., Tome M.E., Briehl M.M., Bauer R., Kaina B. Molecular modes of action of cantharidin in tumor cells. Biochem. Pharmacol. 2005, 69(5):811-818.
8. Rauh R., Kahl S., Boechzelt H., Bauer R., Kaina B., Efferth T. Molecular biology of cantharidin in cancer cells. Chin. Med. 2007, 2:8.
9. Yim H., Lee Y.H., Lee C.H., Lee S.K. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med. 1999, 65(1):9-13.
10. Sawyers C.L Research on resistance to cancer drug Gleevec. Science 2001, 294(5548):1834.
11. Efferth T., Fu Y.J., Zu Y.G., Schwarz G., Konkimalla V.S., Wink M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr. Med. Chem. 2007, 14(19):2024-2032.
12. Efferth T., Giaisi M., Merling A., Krammer P.H., Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2007, 2(1):e693.
13. Efferth T., Rucker G., Falkenberg M., Manns D., Olbrich A., Fabry U., Osieka R. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 1996, 46(2):196-200.
14. Efferth T. Microarray-based prediction of cytotoxicity of tumor cells to cantharidin. Oncol. Rep. 2005, 13(3):459-463.
15. Efferth T., Dunstan H., Sauerbrey A., Miyachi H., Chitambar C.R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 2001, 18(4):767-773.
16. Efferth T., Briehl M.M., Tome M.E. Role of antioxidant genes for the activity of artesunate against tumor cells. Int. J. Oncol. 2003, 23(4):1231-1235.
17. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 2005, 8(1-2):85-97.
18. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48(3):589-601.
19. Foley G.E., Lazarus H., Farber S., Uzman B.G., Boone B.A., McCarthy R.E. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965, 18:522-529.
20. Hori H., Tran P., Carrera C.J., Hori Y., Rosenbach M.D., Carson D.A., Nobori T. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res. 1996, 56(24):5653-5658.
21. Alas S., Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001, 61(13):5137-5144.
22. Sieber S., Gdynia G., Roth W., Bonavida B., Efferth T. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. Int. J. Oncol. 2009, 35(1):149-158.
23. Demers G.W., Foster S.A., Halbert C.L., Galloway D.A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. U.S.A. 1994, 91(10):4382-4386.
24. Halbert C.L., Demers G.W., Galloway D.A. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 1992, 66(4):2125-2134.
25. Boukamp P., Petrussevska R.T., Breitkreutz D., Hornung J., Markham A., Fusenig N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell. Biol. 1988, 106(3):761-771.
26. Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991, 51(16):4226-4233.
27. Storch C.H., Theile D., Lindenmaier H., Haefeli W.E., Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 2007, 73(10):1573-1581.
28. Storch C.H., Ehehalt R., Haefeli W.E., Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp. Ther. 2007, 323(1):257-264.
29. Frohlich M., Albermann N., Sauer A., Walter-Sack I., Haefeli W.E., Weiss J. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem. Pharmacol. 2004, 68(12):2409-2416.
30. Weiss J., Dormann S.M., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J. Pharmacol. Exp. Ther. 2003, 305(1):197-204.
31. Weiss J., Rose J., Storch C.H., Ketabi-Kiyanvash N., Sauer A., Haefeli W.E., Efferth T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 2007, 59(2):238-245.
32. http://dtp.nci.nih.gov/.
33. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81(14):1088-1092.
34. Leteurtre F., Kohlhagen G., Paull K.D., Pommier Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J. Natl. Cancer Inst. 1994, 86(16):1239-1244.
35. Stone S., Dayananth P., Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res. 1996, 56(14):3199-3202.
36. Scherf U, Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., Kohn K.W., Reinhold W.C., Myers T.G., Andrews D.T., Scudiero D.A., Eisen M.B., Sausville E.A., Pommier Y., Botstein D., Brown P.O., Weinstein J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24(3):236-244.
37. Efferth T., Olbrich A., Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 2002, 64(4):617-623.
38. Harris E.H, Burkhart B.D., Gillham N.W., Boynton J.E. Antibiotic resistance mutations in the chloroplast 16S and 23S rRNA genes of Chlamydomonas reinhardtii: correlation of genetic and physical maps of the chloroplast genome. Genetics 1989, 123(2):281-292.
39. Stolovich M., Tang H., Hornstein E., Levy G., Cohen R., Bae S.S., Birnbaum M.J., Meyuhas O. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell. Biol. 2002, 22(23):8101-8113.
40. Chen H., Xie Z.X., Jiang H., Zhang Z.W., Wang G.P. Effect of ribosomal protein L6 on drug resistance and apoptosis in K562/A02 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007, 15(2):292-295.
41. Du J., Shi Y., Pan Y., Jin X., Liu C., Liu N., Han Q., Lu Y., Qiao T., Fan D. Regulation of multidrug resistance by ribosomal protein l6 in gastric cancer cells. Cancer Biol. Ther. 2005, 4(2):242-247.
42. Mori R., Ishiguro H., Kuwabara Y., Kimura M., Mitsui A., Tomoda K., Mori Y., Ogawa R., Katada T., Harata K., Fujii Y. Targeting beta1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma. Oncol. Rep. 2008, 20(6):1345-1351.
43. Stossel T.P., Condeelis J., Cooley L., Hartwig J.H., Noegel A., Schleicher M., Shapiro S.S. Filamins as integrators of cell mechanics and signalling. Nat. Rev. Mol. Cell. Biol. 2001, 2(2):138-145.
44. Li C., Yu S., Nakamura F., Yin S., Xu J., Petrolla A.A., Singh N., Tartakoff A., Abbott D.W., Xin W., Sy M.S. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J. Clin. Invest. 2009, 119(9):2725-2736.
45. Grant S., Qiao L., Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 2002, 7:d376-389.
46. McCubrey J.A, Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773(8):1263-1284.
47. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch P., Weber H.O., Hengstler J.G., Halatsch M.E., Volm M., Tew K.D., Ross D.D., Funk J.O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 2003, 64(2):382-394.
48. Konkimalla V.B., McCubrey J.A., Efferth T. The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. Curr. Cancer Drug Targets 2009, 9(1):72-80.
49. Iiizumi M., Arakawa H., Mori T., Ando A., Nakamura Y. Isolation of a novel gene, CABC1, encoding a mitochondrial protein that is highly homologous to yeast activity of bc1 complex. Cancer Res. 2002, 62(5):1246-1250.
50. Keenan J, Murphy L., Henry M., Meleady P., Clynes M. Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 2009, 9(6):1556-1566.
51. Ahn B.H., Lee J.H., Bae Y.S. Identification of mutations in protein kinase CKIIbeta subunit that affect its binding to ribosomal protein L41 and homodimerization. J. Biochem. Mol. Biol. 2003, 36(4):344-348.
52. Ueno K., Hazama S., Mitomori S., Nishioka M., Suehiro Y., Hirata H., Oka M., Imai K., Dahiya R., Hinoda Y. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br. J. Cancer 2009.
53. Li L.N, Zhang H.D., Yuan S.J., Tian Z.Y., Wang L., Sun Z.X. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int. J. Cancer 2007, 121(6):1360-1365.
54. Konkimalla V.B., Blunder M., Korn B., Soomro S.A., Jansen H., Chang W., Posner G.H., Bauer R., Efferth T. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 2008, 19(2):184-191.
55. Segditsas S., Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006, 25(57):7531-7537.
56. Grim J., D'Amico A., Frizelle S., Zhou J., Kratzke R.A., Curiel D.T. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. Clin. Cancer Res. 1997, 3(12 Pt 1):2415-2423.
57. el-Deiry W.S Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol. 1997, 9(1):79-87.
58. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace A.J., Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57(19):4285-4300.
59. Ganguly N., Parihar S.P. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J. Biosci. 2009, 34(1):113-123.
60. Howie H.L., Katzenellenbogen R.A., Galloway D.A. Papillomavirus E6 proteins. Virology 2009, 384(2):324-334.
61. Liu Z.G., Zhao L.N., Liu Y.W., Li T.T., Fan D.M., Chen J.J. Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents. J. Mol. Biol. 2007, 374(2):334-345.
62. Disbrow G.L., Baege A.C., Kierpiec K.A., Yuan H., Centeno J.A., Thibodeaux C.A., Hartmann D., Schlegel R. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res. 2005, 65(23):10854-10861.
63. Efferth T., Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem. Pharmacol. 2004, 68(1):3-10.
64. Efferth T., Benakis A., Romero M.R., Tomicic M., Rauh R., Steinbach D., Hafer R., Stamminger T., Oesch F., Kaina B., Marschall M. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 2004, 37(7):998-1009.
65. Sinha B.K., Katki A.G., Batist G., Cowan K.H., Myers C.E. Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 1987, 26(13):3776-3781.
66. Singh S.V., Iqbal J., Krishan A. Cytochrome P450 reductase, antioxidant enzymes and cellular resistance to doxorubicin. Biochem. Pharmacol. 1990, 40(2):385-387.
67. Xu B.H, Gupta V., Singh S.V. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int. J. Cancer 1994, 58(5):686-692.
68. Matsura T., Kai M., Jiang J., Babu H., Kini V., Kusumoto C., Yamada K., Kagan V.E. Endogenously generated hydrogen peroxide is required for execution of melphalan-induced apoptosis as well as oxidation and externalization of phosphatidylserine. Chem. Res. Toxicol. 2004, 17(5):685-696.
69. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 2006, 7(4):407-421.
70. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007, 446(7137):749-757.
71. Efferth T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr. Mol. Med. 2001, 1(1):45-65.
72. Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 2007, 1775(2):237-262.
73. Efferth T., Davey M., Olbrich A., Rucker G., Gebhart E., Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis. 2002, 28(2):160-168.